Ngan Bo-Yee, Forte Vito, Campisi Paolo
Division of Pathology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada.
Arch Otolaryngol Head Neck Surg. 2008 Nov;134(11):1170-6. doi: 10.1001/archotol.134.11.1170.
To examine (1) the molecular angiogenic relationship between endothelial and stromal cells of angiofibromas and how this may elucidate the pathogenesis of angiofibromas and (2) the effects of embolization on the expression of angiotrophic factors and proapoptotic and antiapoptotic factors within the tumor.
The expression of mesenchymal and endothelial stem/progenitor cell-associated proteins (MECAPs) such as proangiogenic cytokine vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR1, VEGFR2, and VEGFR3), angiopoietin receptors (Tie-1 and Tie-2), and stem cell subset marker CD133 was assessed by immunohistological staining in 7 embolized angiofibroma specimens. Expression of proapoptotic Bax, antiapoptotic Bcl-2 and Bcl-xL, nuclear proliferation protein MiB-1, and hypoxia-inducible factor 1alpha (Hif-1alpha) in peri-ischemic areas of the embolized angiofibromas was also assessed.
A single pediatric institution.
Seven patients (identified from medical records, January 1, 2001, through December 31, 2005) who were diagnosed as having juvenile angiofibroma and who underwent surgical treatment. Archival tissues were retrieved for immunostaining.
The immunostaining results were evaluated by microscopy and the staining intensities were also recorded.
All angiofibroma specimens expressed the stem cell subset marker CD133 and MECAPs except VEGFR3 (a few cases). In the only case tested, we found evidence of VEGF-induced angiogenic signaling as the expression of phosphorylated VEGFR2 (Tyr951). Endothelial cells expressed VEGFR1 and VEGFR2 and angiopoietin receptors Tie-1 and Tie-2 but not VEGF. In contrast, VEGF was expressed within stromal cells. Viable tumor adjacent to the ischemic areas demonstrated increased staining intensities to VEGFR2, Tie-1, Tie-2 (all cases), and VEGFR3 (2 cases) and increased nuclear proliferation (5%-20%). All cases expressed proapoptotic and antiapoptotic factors, and the expression of Hif-1alpha was unaffected by ischemia.
Stromal cells appear to be similar to mesenchymal stem cells with endothelial differentiation potential in umbilical cord blood cells. Stromal cells support endothelial growth by providing VEGF as a paracrine factor. Under ischemic stress, the embolized tumor tissues show upregulation of angiogenic receptors, retention of Hif-1alpha, and increased nuclear proliferation rates. Specific angiogenesis blockers may represent a novel treatment strategy for angiofibromas.
研究(1)血管纤维瘤内皮细胞与基质细胞之间的分子血管生成关系,以及这如何阐明血管纤维瘤的发病机制;(2)栓塞对肿瘤内血管生成因子、促凋亡因子和抗凋亡因子表达的影响。
通过免疫组织化学染色评估7例栓塞性血管纤维瘤标本中与间充质和内皮干/祖细胞相关蛋白(MECAPs)的表达,如促血管生成细胞因子血管内皮生长因子(VEGF)、VEGF受体(VEGFR1、VEGFR2和VEGFR3)、血管生成素受体(Tie-1和Tie-2)以及干细胞亚群标志物CD133。还评估了栓塞性血管纤维瘤缺血周围区域促凋亡蛋白Bax、抗凋亡蛋白Bcl-2和Bcl-xL、核增殖蛋白MiB-1以及缺氧诱导因子1α(Hif-1α)的表达。
一家儿科机构。
7例(从2001年1月1日至2005年12月31日的病历中识别)被诊断为青少年血管纤维瘤并接受手术治疗的患者。检索存档组织进行免疫染色。
通过显微镜评估免疫染色结果,并记录染色强度。
所有血管纤维瘤标本均表达干细胞亚群标志物CD133和MECAPs,但VEGFR3除外(少数病例)。在唯一检测的病例中,我们发现了VEGF诱导的血管生成信号的证据,即磷酸化VEGFR2(Tyr951)的表达。内皮细胞表达VEGFR1和VEGFR2以及血管生成素受体Tie-1和Tie-2,但不表达VEGF。相反,VEGF在基质细胞中表达。与缺血区域相邻的存活肿瘤显示VEGFR2、Tie-1、Tie-2(所有病例)和VEGFR3(2例)染色强度增加,核增殖增加(5%-20%)。所有病例均表达促凋亡和抗凋亡因子,且Hif-1α的表达不受缺血影响。
基质细胞似乎类似于脐带血细胞中具有内皮分化潜能的间充质干细胞。基质细胞通过提供VEGF作为旁分泌因子来支持内皮生长。在缺血应激下,栓塞的肿瘤组织显示血管生成受体上调、Hif-1α保留以及核增殖率增加。特异性血管生成阻滞剂可能代表一种治疗血管纤维瘤的新策略。